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The anthracycline anticancer agent doxorubicin has been recognised to induce 
a dose-dependent cardiotoxicity. The chronic form of such complication is characte- 
rised by an irreversible cardiac damage and congestive heart failure. Although the 
pathogenesis of anthracycline cardiotoxicity seems to be multifactorial, the pivotal 
role has been attributed to reactive oxygen species formation. Because redox 
equilibrium in cardiomyocytes may be regulated via iodothyronine hormones, the 
aim of the study was to appraise the effect of hypothyroidism on heart damages 
induced by doxorubicin. The rats received methimazole in drinking water (0.001 
and 0.025%) after doxorubicin administration (2.0, 5.0 and 15 mg/kg). The cardiac 
morphology and blood biochemical markers of heart damage were assessed. 
Decreased levels of iodothyronine hormones had not significant impact on cardiac 
morphological changes and no effect on the level of B-type natriuretic peptide in 
rats receiving doxorubicin. Lower hormonal levels had sporadic, diverse effect on 
blood transaminases, lactate dehydrogenase and creatine kinase levels, but any 
relation to time, doxorubicin doses and hypothyroid status was found. Hypothy-
reosis leads to increase in fatty acid binding protein in rats receiving higher dose 
of doxorubicin. Hypothyreosis had no effect on heart stretching and on necrosis at 
morphological level, but caused biochemical symptoms of cardiomyocyte necrosis 
in rats receiving doxorubicin. (Folia Morphol 2013; 72, 4: 340–348)
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INTRODUCTION
Doxorubicin is an effective antineoplastic drug 
used in various neoplasm diseases. The drug use-
fulness is limited by dose-dependent cardiotoxicity, 
which is secondary to generation of reactive oxy-
gen species. Changes in redox equilibrium lead to 
oxidative damages of lipids, proteins and DNA [11, 
13, 21]. The regulation of antioxidative defence is 
multifactorial. Many studies have indicated connec-
tions of iodothyronine hormones with oxidative stress 
[1, 4, 7, 16, 20]. NADPH2 cytochrome P-450 reducta- 
se (P-450R), the main enzyme responsible for the 
doxorubicin-dependent free radical generation, is 
strictly regulated by triiodothyronine (T3) [8, 17] and 
markedly decreased level of this enzyme (30–50%) 
was observed in heart of rats treated with methima-
zole [25, 28]. Moreover, malic enzymes, G6PDH and 
6PDGH, pivotal enzymes connected with glutathione 
reduction, are transcriptionally regulated by T3 [15, 
19]. The oxidative damages in the heart may result in 
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morphological changes, e.g. necrosis, and releasing 
of cytoplasmatic proteins from cardiomyocytes to the 
blood. Thus, the aim of the study was the assessment 
of methimazole-induced hypothyreosis on cardioto-
xicity induced by doxorubicin.
METHODS
Animals and treatment
The study was approved by the Local Ethical Com-
mittee at the Medical University of Lublin. Male Wi-
star rats (180–220 g) were kept under conventional 
laboratory conditions (temperature 22ºC, humidity 
60–70%, 12 h light/dark cycle) and fed with standard 
rodent granulated fodder LSM® (AGROPOL, Poland). 
Food and water were freely available. Animals were 
randomly divided into experimental and control 
groups (7 animal/group). Rats received thyreostatic 
drug — methimazole (methizole; ICN Polfa Rzeszów, 
Poland) in drinking water for 3 weeks at 2 concentra-
tions (0.001 or 0.025%; group METL or METH, respec-
tively). For the remaining time of the experiment only 
filtrate municipal water was administered. 48 h after 
completing methimazole administration, the rats re-
ceived doxorubicin (EBEWE Arzneimittel Ges.m.b.H., 
Austria) at the concentration of 2.0, 5.0 and 15 mg/ 
/kg of the body weight (2DOX+METL, 5DOX+METL, 
15DOX+METL and 2DOX+METH, 5DOX+METH, 
15DOX+METH groups). Doxorubicin hydrochloric 
was dissolved (1:1; v/v) in a saline solution (Cefarm, 
Poland). The other groups were exposed exclusively 
to doxorubicin, but without inducing hypothyreosis 
(2DOX, 5DOX and 15DOX group). The biological ma-
terials (blood and hearts) were collected 4, 48 and 
96 h after doxorubicin administration. In METL and 
METH groups, 48 h after cessation of methimazole, 
rats were administered with saline and after the next 
96 h the biological material was collected for further 
biochemical analyses. A similar procedure was applied 
in control group, in which 96 h after the saline inje-
ction rats were scarificed.
The blood was aspirated from the left ventricle 
during the pentobarbital anaesthesia and the ob-
tained plasma was storage at –75°C. Immediately 
afterwards, the thyroid gland and heart were remo-
ved during autopsy, washed with 20 mL of saline, 
and fixed in the buffered 10% formalin and routinely 
histologically processed to paraffin blocks. Slides 
were stained with hematoxilin and eosin (H+E) and 
evaluated, without the knowledge of the treated-
-group, under light microscope (Olympus BX45; 
Tokyo, Japan).
Determination of plasma biochemical parameters
Triiodothyronine (FT3) and tetraiodothyronine 
(FT4) concentrations in rat plasma were measured 
using commercial reagents (AxSYM; Abbott, USA). 
The sample and antibody — coated microparticles ad-
ded with reagent form an antibody-antigen complex. 
The T3 or T4 — alkaline phosphatase conjugate binds 
to the available site on the anti-T3 (anti-T4) coated 
microparticles. Finally, 4-methylumbeliferyl phospha-
te was added and the fluorescent intensiveness of the 
obtained product was measured. The serum activity 
of aspartate aminotransferase (AST) alanine amino-
transferase (ALT), lactated dehydrogenase (LDH) and 
creatine kinase (CK) were measured using Cormay 
kits (Poland) according to manufacture application 
on Liasys apparatus (Italy).
The determination of rat’s specific fatty acid-
-binding proteins (FABP, Life Diagnostics, Inc., USA), 
cardiac troponin I (cTnI, Life Diagnostics, Inc., USA) 
and B-type natriuretic peptide (BNP-32; Phoenix Phar-
maceuticals, Inc., USA) were measured in the plasma 
according to the manufacture procedures using 
a spectrophotometric reader PowerWave XT (BioTek, 
USA) according to manufacture procedures.
Statistical analysis
The obtained data were analysed using STATISTICA 
5.0. (Statsoft Inc., USA). Statistical significance was 
evaluated by U Mann-Witney test (vs. saline control) 
and by one-way analysis of variance (Kruskal-Wallis 
ANOVA). The post-hoc test (Newman-Keuls) was used 
to verify null hypothesis, according to which the 
lowered thyroid hormones status influence the eva-
luated parameters. All data are expressed as mean ± 
± standard deviation (M ± SD). The value of p < 0.05 
was considered statistically significant.
RESULTS
The morphology examination of thyroid gland 
showed a reduction of follicles colloid in relation to 
the methimazole concentrations (Fig. 1). It was con-
sistent with biochemical markers tested in the blood, 
because significantly decreased FT3 and FT4 serum 
concentrations were found at both tested concen-
tration of methimazole (Table 1). The higher dose of 
the thyreostatic was responsible for the decrease of 
FT3 and FT4 below the limit of detection.
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drug alone and co-treated with methimazole (Fig. 2). 
All morphological changes were time-dependent 
since slightly higher incidence was found in animals 
examined at 48 and 96 h, than in shorter periods. 
Vacuolar and eosinophilic degeneration were the 
most commonly seen in case of cardiomyocytes. 
Microvacuolisation was limited to single cells or 
diffused, whereas macrovacuolisation was found 
less frequently in single, spread cardiomyocytes. In 
some cases, wavy direction of myofibrils, as well as 
cardiomyocytes with strips contractions were also 
observed. 
Among all tested period of time the mean AST 
levels were higher with dose elevation (Table 2). Si-
milarly, it was found for ALT (Table 3) at 48 and 96 h, 
for LDH (Table 4) at 4 and 96 h, and for CK (Table 5) 
at 48 h. In the case of AST, these differences, exclu-
ding 2DOX/4 h, were statistical significant comparing 
with the control. A significant elevation in LDH level 
was observed only for highest dose of doxorubicin 
in all tested time sequences. A significant increase in 
CK activity was found after 5 mg DOX at 4 and 96 h 
and after 15 mg DOX/kg at 48 h. The comparison 
of the activity of all tested enzymes in euthyroid and 
hypothyroid rats treated with lower concentration of 
methimazole and receiving DOX, revealed a signifi-
cant changes in MET0.001%+DOX group at 4 and 96 h, 
but there were no common trend of these changes 
across the doxorubicin doses or time observations. 
Similar comparison for MET0.025%+DOX group (vs. 
DOX) indicated that higher concentration of methi-
mazole led to decrease in AST, ALT and LDH activity. 
However, it was found mainly at 96 h.
Versus control, the FABP (Table 6) and cTnI (Table 7) 
levels were significantly higher after administration 
of the highest doxorubicin dose at 4, 48 and 96 h. 
The middle dose caused marked elevation in cTnI at 
48 and 96 h and FABP at 96 h. Methimazole did not 
change cTnI level in rats treated with doxorubicin. 
However, lower concentration of methimazole led to 
augmentation of increasing level of FABP in group of 
MET0.001%+15DOX at 4 and 48 h.
Cardiac histological abnormalities, both in cardio-
myocytes and interstitial, were observed in most of 
doxorubicin-exposed rats, but their incidence was not 
statistically different between groups exposed to the 
Figure 1. Morphology of thyroid gland (H+E, objective × 20);  
A. Normal morphology (control); B, C. Colloid reduction in rats  
receiving methimazole 0.001 and 0.025%, respectively.
A
B
C
Table 1. Free tetraiodothyronine (FT3) and triiodothyronine (FT4) level (pmol/L; M ± SD)
Control Methimazole
0.001% 0.025%
FT4 10.478 ± 1.118 6.097 ± 1.547* < 2.60**
FT3 3.517 ± 0.495 2.392 ± 0.569* < 1.67**
*p < 0.05 vs. control, **below detection limit
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Figure 2. Cardiac histological changes after doxorubicin administration; A. Normal myocardium (control; H+E; objective ×20); B. Microva-
cuolar degeneration (5 mg DOX/48 h; H+E; objective × 40); C. Intestinal oedema with cardiomyocytes spreading (5 mg DOX/48 h; H+E; 
objective × 40); D. Lesser foci of mononuclear inflammatory cells in myocardium (15 mg DOX/96 h; H+E; objective × 20); E. Eosinophilic 
cardiomyocyte degeneration, wavy direction of myofibrils and macrovacuolar degeneration of the single cardiomyocyte (15 mg DOX/96 h; 
H+E; objective × 40); F. Small foci of cardiomyocytes with high eosinophilic degeneration, loss of striation and shrinkage, hiperchromatic 
nuclei (MET0.001%+15 mg DOX/96 h; H+E; objective × 40); G. Irregular direction of eosinophilic cardiomyocytes with loss of striation in area 
limited by intercalated discs (MET0.001%+15 mg DOX/96 h; H+E; objective × 20).
A
B
C
D
E
F
G
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Table 2. The activity of aspartate aminotransferase (IU/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 2 139.40 ± 25.37 180.00 ± 29.74* 151.60 ± 27.83* 0.1193
5 177.67 ± 52.13* 279.50 ± 79.9* 220.50 ± 73.44* 0.0853
15 275.00 ± 79.14* 490.00 ± 152.80*# 236.20 ± 66.15*# 0.0120
48 h 2 217.40 ± 50.84* 162.20 ± 36.87* 223.40 ± 38.71* 0.1075
5 291.50 ± 74.85* 260.67 ± 150.88* 273.66 ± 93.63* 0.4233
15 364.00 ± 178.84* 379.14 ± 103.47* 510.00 ± 113.42* 0.1078
96 h 2 202.00 ± 28.27* 164.83 ± 43.27* 149.83 ± 16.46* 0.0775
5 248.00 ± 58.68* 95.60 ± 8.73*# 179.40 ± 48.20*#† 0.0029
15 362.60 ± 29.76* 296.60 ± 39.71*# 247.00 ± 73.28*# 0.0435
0.9% NaCl 113.57 ± 14.64 161.20 ± 16.08* 94.60 ± 20.54
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl); #vs. DOX; †vs. MET0.001% + DOX
Table 3. The activity of alanine aminotransferase (IU/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 2 57.20 ± 10.33 69.40 ± 10.38* 62.80 ± 7.73 0.2051
5 56.17 ± 10.99 80.00 ± 17.89*# 64.50 ± 8.78† 0.0213
15 91.00 ± 40.75* 102.14 ± 16.05* 92.60 ± 26.82 0.2603
48 h 2 63.00 ± 14.75 77.00 ± 15.63* 73.00 ± 16.44 0.3432
5 85.66 ± 15.28* 104.00 ± 84.68* 97.33 ± 22.03* 0.2912
15 103.43 ± 33.60* 97.00 ± 18.13* 132.80 ± 18.37* 0.1003
96 h 2 61.20 ± 13.38 55.12 ± 4.26 46.50 ± 5.57*#† 0.0348
5 118.67 ± 63.38* 33.00 ± 8.54*# 63.80 ± 22.97#† 0.0047
15 132.00 ± 71.40* 97.00 ± 54.53 106.20 ± 19.66* 0.4667
0.9% NaCl 56.86 ± 7.31 63.60 ± 12.28 54.00 ± 1.58
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl); #vs. DOX; †vs. MET0.001% + DOX
Table 4. The activity of lactate dehydrogenase (IU/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 2 1462.60 ± 431.28 1788.40 ± 303.67 2046.60 ± 547.04* 0.1791
5 1824.83 ± 446.09 1946.33 ± 662.08 1942.00 ± 349.28* 0.8420
15 2374.86 ± 903.79* 1540.14 ± 239.46 1962.00 ± 681.13* 0.1918
48 h 2 1658.80 ± 486.46 1025.20 ± 325.25 1658.60 ± 506.89 0.0664
5 1607.50 ± 573.69 1055.50 ± 663.24 1339.20 ± 439.84 0.3426
15 2359.43 ± 915.86* 1493.71 ± 392.02 2187.00 ± 735.79* 0.0856
96 h 2 1382.80 ± 849.06 1667.16 ± 717.33# 1346.16 ± 299.13† 0.0322
5 1657.83 ± 520.92 738.40 ± 197.27# 1486.60 ± 388.89† 0.0108
15 2893.20 ± 322.47* 787.20 ± 124.05# 948.40 ± 166.18#† 0.0052
0.9% NaCl 1165.71 ± 549.15 1887.40 ± 597.68 1664.00 ± 648.20
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl); #vs. DOX; †vs. MET0.001% + DOX
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Table 5. The activity of creatine kinase (IU/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 2 2841.00 ± 798.90 2671.20 ± 572.82 2391.20 ± 412.12 0.4807
5 3463.00 ± 509.23* 2412.83 ± 547.63# 2599.66 ± 1035.61† 0.0446
15 3088.14 ± 783.29 2998.28 ± 814.85 2604.50 ± 1064.25 0.5829
48 h 2 2870.60 ± 692.01 2283.80 ± 405.45 2627.40 ± 636.40 0.2947
5 3136.67 ± 670.23 2317.67 ± 1096.23 2662.66 ± 1026.96 0.3429
15 3710.14 ± 347.17* 2895.57 ± 609.39 3198.40 ± 585.83 0.0511
96 h 2 3259.80 ± 570.08 2381.33 ± 738.80# 3643.16 ± 257.38*† 0.0110
5 3550.17 ± 408.08* 3003.00 ± 772.30 3064.80 ± 668.75 0.3668
15 1834.00 ± 707.25 3225.00 ± 411.45# 2081.80 ± 481.31† 0.0128
0.9% NaCl 2453.86 ± 741.43 3345.80 ± 435.89 3023.00 ± 895.33
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl); #vs. DOX; †vs. MET0.001% + DOX
Table 6. The level of fatty acid binding protein of cardiac origin (μg/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 5 8.40 ± 3.09 8.73 ± 2.88 8.04 ± 3.14 0.8285
15 10.53 ± 3.22* 21.80 ± 4.73*# 15.42 ± 4.55* 0.0296
48 h 5 8.85 ± 2.17 8.82 ± 2.42 8.50 ± 4.94 0.8741
15 11.38 ± 2.80* 16.07 ± 3.59*# 14.00 ± 3.11* 0.0314
96 h 5 10.22 ± 2.75* 6.45 ± 2.76 8.82 ± 1.87* 0.1783
15 15.07 ± 4.02* 13.90 ± 4.06* 13.26 ± 3.25* 0.7973
0.9% NaCl 5.78 ± 1.79 4.51 ± 3.41 6.09 ± 2.80
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl); #vs. DOX
Table 7. The level of cardiac troponin I (μg/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 5 0.093 ± 0.031 0.135 ± 0.038* 0.117 ± 0.045 0.2457
15 0.131 ± 0.026* 0.228 ± 0.128* 0.160 ± 0.057* 0.6183
48 h 5 0.168 ± 0.035* 0.119 ± 0.025* 0.115 ± 0.027 0.0581
15 0.198 ± 0.119* 0.273 ± 0.148* 0.236 ± 0.103* 0.5509
96 h 5 0.140 ± 0.031* 0.114 ± 0.027 0.083 ± 0.019 0.0976
15 0.211 ± 0.074* 0.317 ± 0.138* 0.158 ± 0.042* 0.0976
0.9% NaCl 0.069 ± 0.028 0.058 ± 0.030 0.053 ± 0.026
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl)
Higher dose of doxorubicin leads to increase in 
BNP (Table 8) level comparing with the control only at 
96 h. Referring to particular DOX groups, there were 
any significant changes in BNP level in rats receiving 
both doses of methimazole.
DISCUSSION
The aim of the study was to evaluate the effect 
of iodothyronine hormones status (FT3 and FT4) on 
cardiac changes caused by doxorubicin. Dose depen-
dent inhibition of synthesis of iodothyroid hormones 
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resulted from methimazole was confirmed by FT3 and 
FT4 determination in serum and gland morphology. 
Taking into account absence of overt clinical symp-
toms, these results proved that used drinking water 
concentrations of methimazole were proper for tested 
model. The selected drug directly inhibits the synthe-
sis of thyroid hormones by interfering with iodine 
incorporation into tyrosyl residues of thyroglobulin, 
secondary to interfering with the oxidation of iodide 
ion and iodotyrosyl groups through inhibition of the 
peroxidase enzyme. The primary influence on hy-
pothalamus/hypophysis axis was not revealed [1, 27].
In our previous study [12], it was found that hy-
pothyreosis intensifies doxorubicin-related oxidative 
stress. Because oxidative stress may result in cardio-
myocyte apoptosis and/or necrosis, the heart morp-
hology examination and blood markers assessment 
were conducted.
In most rats from DOX and DOX+MET groups, there 
were histopathological changes both in cardiomyocy-
tes and interstitium. The frequency of these changes 
could be shown in following order: microwascular de-
generation > macrovascular degeneration > increased 
eosinophilic cytoplasm > wavy direction of myofibrils. 
Similar to current study, pathological doxorubicin-rela-
ted changes were seen in cardiomyocytes and cardiac 
interstitium. Generally, these changes are typical for 
doxorubicin. In Arola et al. study [5] rat’s cardiomyocytes 
vacuolisation was observed after doxorubicin admini-
stration at dose of 2.5 mg/kg. Furthermore, micro- and 
macrovacuolisation was found 120 h after doxorubicin 
injection at dose of 10 mg/kg [14]. However, no marked 
changes even at dose up to 25 mg/kg were found in 
mice by Liu et al. [18]. Although hypothyreosis inten-
sified oxidative stress in the heart [12], there were no 
marked differences in morphological changes among 
DOX and DOX+MET groups.
A significant elevation in both serum transamina-
ses level in most groups of rats receiving only doxo- 
Table 8. The level of B-type natriuretic peptide (μg/L; M ± SD)
DOX [mg/kg] Methimazole ANOVA
0.000% 0.001% 0.025% p
4 h 15 0.664 ± 0.282 0.502 ± 0.188* 0.374 ± 0.159* 0.3076
48 h 15 0.620 ± 0.282 0.476 ± 0.128* 0.358 ± 0.133* 0.1103
96 h 15 0.508 ± 0.188* 0.445 ± 0.208* 0.302 ± 0.100* 0.3465
0.9% NaCl 0.946 ± 0.275 0.772 ± 0.154 0.7380.304
DOX — doxorubicin; *p < 0.05 vs. control (0.9% NaCl)
rubicin was revealed, but AST was more sensitive 
marker than ALT. For instance, any changes in ALT 
level compared with the control was found at the 
lowest dose of doxorubicin and additionally relative 
elevations of AST compared with the control were 
higher than ALT. These results are in agreement with 
previous studies by Al-Shabanah et al. [3] and Buyu-
kokuroglu et al. [6] who exposed rats to doxorubicin 
(15 or 20 mg/kg) and observed significant increase 
in AST activity after 24 and 48 h, respectively. Yag-
murca et al. [29] revealed that AST activity remains 
elevated even 10 days after treatment with 20 mg of 
doxorubicin/kg. Taking into account that AST is mainly 
localised in mitochondria [26], observed increase in 
AST in the blood may suggest serious cells dysfun-
ction. The hypothyreosis influence on changes caused 
by doxorubicin in both transaminases activity was 
found very rare. These changes were dependent on 
the stage of hyperthyreosis and study duration. In 
most cases hypothyreosis diminished transaminases 
activity elevated by doxorubicin, thus reducing toxic 
effect caused by this anticancer drug.
Among doxorubicin alone treated group, the sig-
nificant increase in LDH levels were revealed in all 
tested periods of time only at highest dose of this 
drug. These results are consistent with the previously 
reported results which had shown an elevation in LDH 
activity in rats receiving single and repeated doses of 
doxorubicin [2, 9, 10]. Significant increase in total 
LDH activity and cardiac isoform activity was also 
described by Al-Shabanah et al. [3] even at 3 h after 
treatment with 15 mg doxorubicin/kg, what implies 
that source of the enzyme can be cardiomyocytes. 
Effect of hypothyreosis on LDH changes caused by 
doxorubicin was seen in 4 cases — only at 96 h. In 
3 of these cases LDH activity was lower than in co-
unterpart group of DOX, suggesting, similarly as in 
transaminase case, that hypothyreosis has diminished 
harmful effect of doxorubicin.
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An increase in LDH activity in group exposed exclusi-
vely to doxorubicin was not associated with CK changes, 
which abnormalities was notice occasionally in every 
tested period of time. The significant increase in CK 
activity was also observed in the studies when doxoru-
bicin was administered as single or repeated doses [2, 
9]. In the study by Al-Shabanach et al. [3] significant 
increase in both, total and cardiac isoform of CK was 
observed in rats 24 h after doxorubicin administration 
(15 mg/kg), suggesting that source of the enzymes 
might be cardiomyocytes. In the current study, signifi-
cant changes in blood CK levels between doxorubicin 
treated euthyroid and hypothyroid rats were found ac-
cidentally. The marked decrease in CK activity was noted 
in MET0.001%+DOX5mg group. Moreover, the changes 
observed in 96 h are similar to theses observed for LDH.
Changes in FABP and cTnI levels may be explained 
by cardiomyocyte damages, less likely by necrosis, 
since lack of histological features of such complication 
were revealed. Normal range of FABP in humans and 
rats is about on the same level [23, 24]. The method 
applied for cTnI monitoring was previously tested by 
O’Brien et al. [22] who confirmed that it is sensitive 
and specific method to study cardiac damages in rats.
The elevated blood level of FABP and cTnI was found 
in prevalent DOX tested group that was associated with 
cardiac histological changes. However, the effect of 
methimazole on the doxorubicin cardiac toxicity, stated 
on the basis of FABP status, was revealed only in rats 
receiving lower dose of thyreostatic drug at 4 and 48 h, 
only after maximum dose of doxorubicin used in the 
study. There were insignificant changes in the level of 
BNP between euthyroid and hypothyroid rats receiving 
doxorubicin. Thus, it indicates that hypothyreosis had no 
effect on heart stretching in rats receiving doxorubicin.
Decreased level of iodothyronine hormones had 
no impact on cardiac morphological changes and 
heart stretching in rats receiving doxorubicin. Lower 
hormonal status had sporadic, diverse effect on blood 
transaminases, LDH and CK levels, but any relation to 
time, doxorubicin doses and hypothyroid status was 
found. Elevated level of FABP in rats with hypothyreo-
sis and receiving doxorubicin, suggests sub-cellular 
disturbance of cardiomyocytes.
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